Crohn's and Colitis Congress 2022

Special diet may help reduce disease activity in IBD

IBD: Does certain diet help?

Pearl Toh, 20220226143000

Diet plays an important role in reducing disease activity in patients with inflammatory bowel disease (IBD) — particularly when diet leans towards anti-inflammatory food or a CD exclusion diet (CDED), according to studies presented at the Crohn’s and Colitis Congress (CCC) 2022.

Starting vedolizumab early better than late for UC

Elvira Manzano, 20220221000000

Starting vedolizumab early after the diagnosis of ulcerative colitis (UC) appeared more effective than delaying it to after initiation of other UC treatments, according to the RALEE study.

COVID-19 infection relatively rare in vaccinated IBD patients

Roshini Claire Anthony, 20220215180001

Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.

Long-term PEN therapy promising in children with mild Crohn’s disease

Jairia Dela Cruz, 20220214140000

Partial enteral nutritional (PEN) therapy shows potential in the long-term management of mild paediatric Crohn’s disease, helping to avoid the use of corticosteroids and prevent side effects commonly observed with other inflammatory bowel disease therapies, according to a study presented at the virtual Crohn's & Colitis Congress.

Delaying endoscopies due to COVID-19 safe in IBD patients

Tristan Manalac, 20220214090000

Delays in endoscopies due to the coronavirus disease 2019 (COVID-19) pandemic does not seem to worsen clinical outcomes in patients with inflammatory bowel diseases (IBD), though healthcare utilization patterns appear to be affected, according to a study reported at the recently concluded 2022 Crohn’s & Colitis Congress (CCC 2022).

No benefit to adding 5-ASAs to steroids in acute severe UC

Roshini Claire Anthony, 20220211180001

The addition of 5-aminosalicylic acid (5-ASA) to standard corticosteroid treatment did not improve outcomes in patients hospitalized with acute severe ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2022.

Wearable sweat sensing device can signal IBD flare-ups

Jairia Dela Cruz, 20220211140000

A wearable device that continuously measures inflammatory bowel disease (IBD) biomarkers from sweat can distinguish between healthy and IBD patients and, as such, be used to monitor biomarker levels in real-time to flag an impending flare-up, as shown in a study.

Sleep problems plague IBD patients, require more attention

Stephen Padilla, 20220211120000

The opinion that inflammatory bowel disease (IBD) is associated with poor sleep is not uncommon among patients with IBD, according to a study. Moreover, these individuals tend to think and behave in manners that worsen sleep and their disease.

How do UC patients define severe bowel urgency, meaningful change?

Tristan Manalac, 20220211090000

Ulcerative colitis (UC) patients appear to be in general agreement about what constituted “mild” and “moderate” bowel urgency on an 11-point scale, reports a recent study presented at the 2022 Crohn’s & Colitis Congress (CCC 2022).

Intestinal ultrasound picks up CD recurrence post-op

Elvira Manzano, 20220211000000

Intestinal ultrasound could be a simple, effective, and noninvasive tool for detecting the recurrence of Crohn’s disease (CD) after surgery, according to an expert at CCC 2022.